Blockade of the CCL2/CCR2 axis markedly reduces the rate at which BC progresses by preventing the accumulation of TAMs in the Br-TME and increasing the antitumor efficacy of surrounding CD8+ T cells [192]. The gene discussed is CCR2; the disease is breast cancer.